top of page

Inflection Biosciences Shortlisted for The Pharma Industry Awards 2015

Dublin, Ireland, July 29, 2015 – Inflection Biosciences Ltd, a private company developing highly innovative treatments for cancer, today announced that it has been shortlisted in the ‘Biotech Company of the Year’ and ‘Partnership Alliance of the Year’ categories at the Pharma Industry Awards 2015. Inflection Biosciences previously won the ‘Start-up Company of the Year’ at the Pharma Industry Awards 2014.

The Biotech Company of the Year award is open to any company or organisation working on the cutting edge of biotechnology. It is designed to recognise entrepreneurs for their achievements in the commercialisation of biological processes to research and develop medicines and pharmaceutical agents.

The Partnership Alliance of the Year award will recognise innovative collaborations, both internally and externally, in Ireland’s Pharma industry, particularly where there is evidence of a strong strategic partnership involving commercial inputs for both partners. Inflection Biosciences’ collaboration with Trinity College Dublin, which is exploring the effectiveness of Inflection Biosciences’ innovative treatments in treatment resistant lung cancer, has been shortlisted in this category.

The Pharma Industry Awards recognise and celebrate the most original and innovative individuals and companies that demonstrate excellence in the Irish Pharma sector. The winners will be announced at The Pharma Industry Awards 2015 on Thursday, October 22nd at the Ballsbridge Hotel, Dublin 4. For more information please visit

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises IBL-202 (PIM/PI3K inhibitor) and IBL-301 (PIM/PI3K/mTOR inhibitor), selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit


bottom of page